Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380625862> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4380625862 abstract "Abstract Background and Aims Secondary atypical hemolytic uremic syndrome (secondary aHUS) is a heterogeneous group of thrombotic microangiopathies (TMA) associated with various underlying conditions. Unlike primary aHUS, there is still no hard evidence on the efficacy of complement blockade in treating secondary aHUS since the two main series in the literature that investigate this subject show discrepant results. Our work aims to reassess Eculizumab's efficacy in treating secondary aHUS. Method Observational, retrospective, single-center study, in which we analyzed the hematological and renal evolution of 24 patients diagnosed with secondary aHUS who received treatment with Eculizumab compared with a control cohort of 14 patients who did not receive Eculizumab. Complete renal response was defined as the recovery of renal function before the event, partial renal response as a recovery of 50% of lost glomerular filtration rate, and hematological response as normalization of hemoglobin and platelets. Results We found no statistically significant differences in baseline characteristics or disease severity between both groups. After a median of 5 doses of Eculizumab, the group of patients who received complement blockade presented a significant difference in renal response (complete in 47.8% of patients and partial in 17.4%) compared to the control cohort (complete response 14.3% and partial of 14.3%). Rates of hematological remission were similar in both groups (87% in the eculizumab cohort and 85.7% in the control cohort). Conclusion Rational and early use of Eculizumab in patients with secondary aHUS could be an effective and safe therapeutic option, guaranteeing better renal recovery compared to patients who do not receive complement blockade." @default.
- W4380625862 created "2023-06-15" @default.
- W4380625862 creator A5032567197 @default.
- W4380625862 creator A5036829584 @default.
- W4380625862 creator A5036894659 @default.
- W4380625862 creator A5049224814 @default.
- W4380625862 creator A5058175617 @default.
- W4380625862 creator A5065040595 @default.
- W4380625862 creator A5067440092 @default.
- W4380625862 creator A5069489546 @default.
- W4380625862 creator A5077899475 @default.
- W4380625862 creator A5081208174 @default.
- W4380625862 date "2023-06-01" @default.
- W4380625862 modified "2023-09-27" @default.
- W4380625862 title "#5163 RATIONAL USE OF ECULIZUMAB IN SECONDARY ATYPICAL HAEMOLYTIC UREMIC SYNDROME" @default.
- W4380625862 doi "https://doi.org/10.1093/ndt/gfad063c_5163" @default.
- W4380625862 hasPublicationYear "2023" @default.
- W4380625862 type Work @default.
- W4380625862 citedByCount "0" @default.
- W4380625862 crossrefType "journal-article" @default.
- W4380625862 hasAuthorship W4380625862A5032567197 @default.
- W4380625862 hasAuthorship W4380625862A5036829584 @default.
- W4380625862 hasAuthorship W4380625862A5036894659 @default.
- W4380625862 hasAuthorship W4380625862A5049224814 @default.
- W4380625862 hasAuthorship W4380625862A5058175617 @default.
- W4380625862 hasAuthorship W4380625862A5065040595 @default.
- W4380625862 hasAuthorship W4380625862A5067440092 @default.
- W4380625862 hasAuthorship W4380625862A5069489546 @default.
- W4380625862 hasAuthorship W4380625862A5077899475 @default.
- W4380625862 hasAuthorship W4380625862A5081208174 @default.
- W4380625862 hasBestOaLocation W43806258621 @default.
- W4380625862 hasConcept C111684460 @default.
- W4380625862 hasConcept C126322002 @default.
- W4380625862 hasConcept C159641895 @default.
- W4380625862 hasConcept C159654299 @default.
- W4380625862 hasConcept C167135981 @default.
- W4380625862 hasConcept C203014093 @default.
- W4380625862 hasConcept C2777637130 @default.
- W4380625862 hasConcept C2777878052 @default.
- W4380625862 hasConcept C2777991916 @default.
- W4380625862 hasConcept C2779134260 @default.
- W4380625862 hasConcept C71924100 @default.
- W4380625862 hasConcept C72563966 @default.
- W4380625862 hasConcept C90924648 @default.
- W4380625862 hasConceptScore W4380625862C111684460 @default.
- W4380625862 hasConceptScore W4380625862C126322002 @default.
- W4380625862 hasConceptScore W4380625862C159641895 @default.
- W4380625862 hasConceptScore W4380625862C159654299 @default.
- W4380625862 hasConceptScore W4380625862C167135981 @default.
- W4380625862 hasConceptScore W4380625862C203014093 @default.
- W4380625862 hasConceptScore W4380625862C2777637130 @default.
- W4380625862 hasConceptScore W4380625862C2777878052 @default.
- W4380625862 hasConceptScore W4380625862C2777991916 @default.
- W4380625862 hasConceptScore W4380625862C2779134260 @default.
- W4380625862 hasConceptScore W4380625862C71924100 @default.
- W4380625862 hasConceptScore W4380625862C72563966 @default.
- W4380625862 hasConceptScore W4380625862C90924648 @default.
- W4380625862 hasIssue "Supplement_1" @default.
- W4380625862 hasLocation W43806258621 @default.
- W4380625862 hasOpenAccess W4380625862 @default.
- W4380625862 hasPrimaryLocation W43806258621 @default.
- W4380625862 hasRelatedWork W1908862090 @default.
- W4380625862 hasRelatedWork W2072874604 @default.
- W4380625862 hasRelatedWork W2077986770 @default.
- W4380625862 hasRelatedWork W2128719952 @default.
- W4380625862 hasRelatedWork W2141534367 @default.
- W4380625862 hasRelatedWork W2555063840 @default.
- W4380625862 hasRelatedWork W2588054188 @default.
- W4380625862 hasRelatedWork W2997675070 @default.
- W4380625862 hasRelatedWork W4280572460 @default.
- W4380625862 hasRelatedWork W4280613612 @default.
- W4380625862 hasVolume "38" @default.
- W4380625862 isParatext "false" @default.
- W4380625862 isRetracted "false" @default.
- W4380625862 workType "article" @default.